Nephrology Dialysis Transplantation Reports Phase 2 Data of Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Shows Improved Hemoglobin Levels in Non-Dialysis CKD Subjects With Anemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Nephrology Dialysis Transplantation Reports Phase 2 Data of Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Shows Improved Hemoglobin Levels in Non-Dialysis CKD Subjects With Anemia
(NASDAQ: FGEN) Delayed: 9.71 --0 (-0%)
Previous Close $9.71    52 Week High $31.90 
Open $9.71    52 Week Low $14.38 
Day High $9.71    P/E N/A 
Day Low $9.71    EPS $0.00 
Volume 77,000